These findings establish cell-cycle dysregulation as a central pathogenic mechanism in C9orf72 ALS/FTD and highlight CDK4/6 signaling as a promising therapeutic target. This evidence concerns the gene C9orf72 and amyotrophic lateral sclerosis.